肿瘤多肽疫苗研究进展  

Advance on Antitumor Peptide Vaccines

作　　者：万岩岩 钟静静[1] 高宁宁[1] 刘宇[1] 黄馨萍 刘兵[1] 王竹林[1] 靳广毅[1] 刁昱文[1] 

机构地区：[1]深圳大学肿瘤研究中心合成生物学工程实验室,广东深圳518060

出　　处：《动物医学进展》2015年第2期101-105,共5页Progress In Veterinary Medicine

基　　金：深圳市战略新兴产业发展专项(JCYJ20130326110057374)

摘　　要：肿瘤的发生、发展和治疗与机体免疫系统功能密切相关,伴随着肿瘤抗原、抗原递呈、T细胞识别机制的突破性研究进展,研究者发现抗肿瘤多肽疫苗能够通过肿瘤抗原多肽识别抗原递呈细胞表面的主要组织相容性复合体(MHC)分子,形成肽-MHC-T细胞受体复合物,引起相应的细胞毒性T淋巴细胞免疫反应,从而杀伤肿瘤。因此,研制既能打破肿瘤患者存在的免疫耐受又能诱发针对肿瘤相关抗原特异性免疫应答的高效多肽疫苗已成为肿瘤免疫治疗研究的热点。论文综述了肿瘤多肽疫苗抗肿瘤相关机制及其在该领域所取得的最新临床研究进展。It＇s well known that the immune system is closely related to the genesis, progression and clinical responses of the tumor. With the breakthrough development of the research on tumor antigen, antigen presentation and T cell recognition mechanism, antitumor peptide vaccine can produce the peptide-MHC-T cell receptor （TCR） complex by delivering the tumor antigen to the major histocompatibility complex （MHC） of antigen presenting cells（APC）, causing cytotoxic T lymphocyte （CTL） response, which can kill tumor cells. It has become the keen point on the tumor immunotherapy to develop the efficient peptide vaccines that may own the capacity of breaking immunological tolerance and elieiting tumor-associated antigen （TAAs）- specific immunity in a majority of patients. This article reviewed how antitumor peptide vaccine had occurred and developed, adding to the latest clinical research progress in this field.

关 键 词：抗肿瘤多肽疫苗 免疫治疗 肽-MHC-TCR复合物 临床研究 

分 类 号：R730.51[医药卫生—肿瘤]